BioCardia Files 8-K for Other Events & Exhibits
Ticker: BCDA · Form: 8-K · Filed: Jan 31, 2024 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Jan 31, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, corporate-governance
TL;DR
**BioCardia filed a routine 8-K, signaling potential upcoming news; watch for details.**
AI Summary
BioCardia, Inc. filed an 8-K on January 31, 2024, to report 'Other Events' and 'Financial Statements and Exhibits'. This filing primarily serves to update the public record regarding the company's current status and any recent material events, though the specific details of these events are not provided within this particular excerpt. For investors, this matters because 8-K filings are crucial for transparency, signaling that the company is adhering to regulatory requirements and potentially indicating upcoming news or changes that could impact stock value.
Why It Matters
This filing indicates BioCardia is updating its public record, which is a standard regulatory compliance step. Investors should monitor subsequent filings or announcements for the specific details of the 'Other Events' mentioned.
Risk Assessment
Risk Level: low — This 8-K is a procedural filing and does not inherently present new risks or opportunities without further context on the 'Other Events' it references.
Analyst Insight
A smart investor would note this routine filing and await further specific disclosures regarding the 'Other Events' mentioned, as this 8-K itself provides no actionable financial information.
Key Players & Entities
- BioCardia, Inc. (company) — the registrant filing the 8-K
- January 31, 2024 (date) — date of the earliest event reported and filing date
- 320 Soquel Way, Sunnyvale, California 94085 (address) — principal executive offices of BioCardia, Inc.
- 0000925741 (number) — BioCardia's Central Index Key (CIK)
- 001-38999 (number) — BioCardia's SEC File Number
FAQ
What is the primary purpose of BioCardia, Inc.'s 8-K filing dated January 31, 2024?
The primary purpose of BioCardia, Inc.'s 8-K filing dated January 31, 2024, is to report 'Other Events' and 'Financial Statements and Exhibits' as per Item Information.
What is BioCardia, Inc.'s Central Index Key (CIK) according to the filing?
BioCardia, Inc.'s Central Index Key (CIK) is 0000925741, as stated in the 'FILER: COMPANY DATA' section.
Where are BioCardia, Inc.'s principal executive offices located?
BioCardia, Inc.'s principal executive offices are located at 320 Soquel Way, Sunnyvale, California 94085, as detailed in the 'BUSINESS ADDRESS' section.
What is the registrant's telephone number, including area code, as provided in the filing?
The registrant's telephone number, including area code, is (650) 226-0120, as stated in the 'Registrant’s telephone number' section.
Under which SEC Act is this 8-K filing made?
This 8-K filing is made under the 1934 Act, as indicated in the 'FILING VALUES' section.
Filing Stats: 452 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-01-31 07:00:22
Key Financial Figures
- $0.001 B — h registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Warrant
Filing Documents
- bcda20240130_8k.htm (8-K) — 28KB
- ex_621126.htm (EX-99.1) — 17KB
- 0001437749-24-002611.txt ( ) — 194KB
- bcda-20240131.xsd (EX-101.SCH) — 4KB
- bcda-20240131_def.xml (EX-101.DEF) — 13KB
- bcda-20240131_lab.xml (EX-101.LAB) — 17KB
- bcda-20240131_pre.xml (EX-101.PRE) — 13KB
- bcda20240130_8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On January 31, 2024, BioCardia, Inc. (the "Company") issued a press release announcing that two scientific abstracts on its CardiAMP and its CardiALLO clinical stage therapeutic programs have been accepted for presentation at the Technology and Heart Failure Therapeutics Conference being held March 4-6, 2024, in Boston, MA. Both abstracts will be presented in the Late-Breaking Clinical Science/First-In-Human & Early Feasibility Studies session on Monday March 4, 2024.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 104 BioCardia, Inc. press release dated January 31, 2024 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: January 31, 2024